FTSE 100 closes at third successive new high but retailers lag
FTSE 100 closed in London around 14 points higher at 7,762
Company
Hemogenyx Pharmaceuticals PLC
LON:HEMO
Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
128 stories · page 7 of 7
FTSE 100 pops higher again to another record close
It was another quiet day in London but also another record close
Archive
Proactive news snapshot: Advanced Oncotherapy, Wishbone Gold, Brave Bison Group ….
A glance at some of the day's highlights from the Proactive Investors newswire
S & U shifts into reverse despite continued strong growth
The share price fall in S&U was a bit mystifying; perhaps it was a further slight deterioration in the impairment percentage
Investments and investor services
Hemogenyx happy with progress and recent collaborations
The biotech, which listed in October, is developing two therapies to improve the chances of survival of people requiring a bone marrow transplant
Investments and investor services
FTSE 100 closes in red as market awaits US jobs report
UK stocks could do with a catalyst and tomorrow's US jobs numbers might provide it
Newmark in demand as its subsidiary secures new supply agreement with long-term customer
Some of the major news-driven risers and fallers in London on Monday ...
Investments and investor services
Hemogenyx aims for revolution in blood cancer treatment
Current standard of care treatment involves chemotherapy and radiotherapy and ultimately, in recurring cases, a bone marrow transplant